1. Genentech, Inc. (74 from 3,217 patents)

2. Cytomx Therapeutics, Inc. (17 from 84 patents)

3. Other (2 from 832,575 patents)

4. Genetech, Inc. (1 from 98 patents)

5. F. Hoffmann-la Roche Ag (166 patents)

1. 12139543 - Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFR

2. 11992528 - Compositions and methods for conjugating activatable antibodies

3. 11890354 - Activatable antibodies that bind epidermal growth factor receptor and methods thereof

4. 11180562 - Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-related disorder by administering activatable EGFR-binding antibodies

5. 11161906 - Multispecific antibodies, multispecific activatable antibodies and methods of using the same

6. 10894821 - Activatable antibodies having non-binding steric moieties and methods of using the same

7. 10709799 - Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

8. 10533053 - Nucleic acids encoding activatable antibodies that bind epidermal growth factor receptor

9. 10301380 - Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof

10. 9889211 - Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

11. 9856314 - Activatable antibodies having non-binding steric moieties and methods of using the same

12. 9688748 - Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof

13. 9676868 - Humanized anti-factor D antibodies and uses thereof

14. 9545442 - Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

15. 9540440 - Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof